Here are four notes:
1. Five analysts have an “outperform” rating on the shares and two analysts gave the shares a “hold” rating.
2. No analysts have an “underperform” or “sell” rating on LDR shares.
3. On Feb. 18, BMO Capital Markets reiterated LDR’s “market perform” rating.
4. BMO analysts had a price target of $23 on LDR shares on Feb. 18.
More articles on devices:
Globus Medical 2015 net income hits $112.8M: 6 things to know
Neurosurgery device developer addresses market demand for new brain technologies: 6 notes
CoNextions Medical to introduce tendon repair device at AAOS meeting: 3 quick notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
